Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Mulholland

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Immunotherapy|July 7, 2016
Antibody-targeted nanoparticles for cancer treatmentThomas Carter, Paul Mulholland, Kerry Chester
Applied Ergonomics|February 8, 2005
Supporting continuous learning in a large organization: the role of group and organizational perspectivesPaul Mulholland, Zdenek Zdrahal, John Domingue
CNS Oncology|October 27, 2016
Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytomaNicholas F Brown, Thomas Carter, Paul Mulholland
Studies in Health Technology and Informatics|April 2, 2013
Sharing and reusing multimedia multilingual educational resources in medicineZdenek Zdrahal, Petr Knoth, Paul Mulholland, et al.
CNS Oncology|October 7, 2017
Dabrafenib and trametinib in BRAFV600E mutated gliomaNicholas F Brown, Thomas Carter, Neil Kitchen, et al.
Future Science OA|March 8, 2016
<i>HOT</i> mutation screening in human glioblastomasDaniel Krell, Paul Mulholland, Justin Stebbing, et al.
British Journal of Cancer|November 6, 2018
Harnessing the immune system in glioblastomaNicholas F Brown, Thomas J Carter, Diego Ottaviani, et al.
Cancers|December 23, 2023
Therapeutic Targeting of Glioblastoma and the Interactions with Its MicroenvironmentVassilis Genoud, Ben Kinnersley, Nicholas F Brown, et al.
Plos One|June 1, 2011
Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastomaDaniel Krell, Mawuelikem Assoku, Malcolm Galloway, et al.
Future Oncology (London, England)|December 4, 2013
IDH mutations in tumorigenesis and their potential role as novel therapeutic targetsDaniel Krell, Paul Mulholland, Adam E Frampton, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Immunotherapy|July 7, 2016
Antibody-targeted nanoparticles for cancer treatmentThomas Carter, Paul Mulholland, Kerry Chester
Applied Ergonomics|February 8, 2005
Supporting continuous learning in a large organization: the role of group and organizational perspectivesPaul Mulholland, Zdenek Zdrahal, John Domingue
CNS Oncology|October 27, 2016
Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytomaNicholas F Brown, Thomas Carter, Paul Mulholland
Studies in Health Technology and Informatics|April 2, 2013
Sharing and reusing multimedia multilingual educational resources in medicineZdenek Zdrahal, Petr Knoth, Paul Mulholland, et al.
CNS Oncology|October 7, 2017
Dabrafenib and trametinib in BRAFV600E mutated gliomaNicholas F Brown, Thomas Carter, Neil Kitchen, et al.
Future Science OA|March 8, 2016
<i>HOT</i> mutation screening in human glioblastomasDaniel Krell, Paul Mulholland, Justin Stebbing, et al.
British Journal of Cancer|November 6, 2018
Harnessing the immune system in glioblastomaNicholas F Brown, Thomas J Carter, Diego Ottaviani, et al.
Cancers|December 23, 2023
Therapeutic Targeting of Glioblastoma and the Interactions with Its MicroenvironmentVassilis Genoud, Ben Kinnersley, Nicholas F Brown, et al.
Plos One|June 1, 2011
Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastomaDaniel Krell, Mawuelikem Assoku, Malcolm Galloway, et al.
Future Oncology (London, England)|December 4, 2013
IDH mutations in tumorigenesis and their potential role as novel therapeutic targetsDaniel Krell, Paul Mulholland, Adam E Frampton, et al.
Pageof 4